hrvatski

Comparison of two immunoassays for CA19-9, CEA and AFP tumor markers

Introduction: Monoclonal antibodies are used to detect serum antigens associated with specific malignancies. These tumor markers are most useful for monitoring response to therapy and detecting early relapse, but results obtained by different assays vary, and a change of method during follow-up may cause problems. The aim of our study was to perform the analytical evaluation of the inter-assay comparability for tumor markers CA19-9, CEA and AFP on two different automated chemistry analyzers. Materials and methods: CA19-9, CEA and AFP concentrations, using Vitros ECi (Ortho Clinical Diagnostics, Johnson and Johnson, Buckinghamshire, UK), and Cobas e 411 (Hitachi High Technologies Corporation, Tokyo, Japan) immunoassay analyzers, were determined. Between-method correlation was studied in 38 serum samples for CA19-9 and AFP and 39 serum samples for CEA. Results: The values of commercial controls were within the range declared by the manufacturer for all tumor markers included in the study on both analyzers. The highest deviation from the declared control values was found for CA19-9 on Vitros ECi and for AFP on Cobas e411 analyzer. High correlation was found between methods for all of three tumor markers studied (R = 0.978 for CA19-9 ; R = 0.995 for CEA and R = 0.999 for AFP). Passing-Bablok regression slope and y- axis intercept included 1 and 0 only for AFP comparative assays. Conclusion: Study results showed the best compliance of values for AFP obtained on two studied immunoassay analyzers. Regardless of high correlations, Passing-Bablok regression indicated lower comparability between two immunoassays for CEA and CA19-9. As the study results confirmed the observations from daily routine, it is of utmost importance for individual patients to be monitored using the same immunoassay and reagents on the same analyzer.

tumor markers ; carbohydrate antigen 19-9 ; alpha-fetoprotein ; carcinoembryonic antigen ; immunoassay

nije evidentirano

engleski

Comparison of two immunoassays for CA19-9, CEA and AFP tumor markers

Introduction: Monoclonal antibodies are used to detect serum antigens associated with specific malignancies. These tumor markers are most useful for monitoring response to therapy and detecting early relapse, but results obtained by different assays vary, and a change of method during follow-up may cause problems. The aim of our study was to perform the analytical evaluation of the inter-assay comparability for tumor markers CA19-9, CEA and AFP on two different automated chemistry analyzers. Materials and methods: CA19-9, CEA and AFP concentrations, using Vitros ECi (Ortho Clinical Diagnostics, Johnson and Johnson, Buckinghamshire, UK), and Cobas e 411 (Hitachi High Technologies Corporation, Tokyo, Japan) immunoassay analyzers, were determined. Between-method correlation was studied in 38 serum samples for CA19-9 and AFP and 39 serum samples for CEA. Results: The values of commercial controls were within the range declared by the manufacturer for all tumor markers included in the study on both analyzers. The highest deviation from the declared control values was found for CA19-9 on Vitros ECi and for AFP on Cobas e411 analyzer. High correlation was found between methods for all of three tumor markers studied (R = 0.978 for CA19-9 ; R = 0.995 for CEA and R = 0.999 for AFP). Passing-Bablok regression slope and y- axis intercept included 1 and 0 only for AFP comparative assays. Conclusion: Study results showed the best compliance of values for AFP obtained on two studied immunoassay analyzers. Regardless of high correlations, Passing-Bablok regression indicated lower comparability between two immunoassays for CEA and CA19-9. As the study results confirmed the observations from daily routine, it is of utmost importance for individual patients to be monitored using the same immunoassay and reagents on the same analyzer.

tumor markers ; carbohydrate antigen 19-9 ; alpha-fetoprotein ; carcinoembryonic antigen ; immunoassay

nije evidentirano